Welcome to our dedicated page for WATERS /DE/ SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WATERS /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WATERS /DE/'s regulatory disclosures and financial reporting.
Waters Corporation (NYSE: WAT) filed an 8-K to disclose a material strategic transaction. The company has signed an agreement to combine Becton, Dickinson & Company’s (BD) Biosciences and Diagnostics Solutions business with Waters (the “Proposed Transaction”). No financial terms, deal value, or pro-forma forecasts were provided in the filing.
Key highlights
- Transaction scope: The combination would add BD’s Biosciences and Diagnostics Solutions unit to Waters’ existing analytical-instrument franchise, potentially expanding Waters’ end-market exposure from life-science research into clinical diagnostics.
- Communication timeline: A joint conference call and webcast was scheduled for 8:00 a.m. ET on 14 July 2025. The related press release (Ex. 99.1) and investor presentation (Ex. 99.2) are furnished—but not filed—under Regulation FD.
- Regulatory & shareholder approvals: Completion is subject to customary closing conditions, including Waters shareholder approval and multiple regulatory clearances.
- Forward-looking statements & risks: Waters lists 17 specific risk factors that could cause the deal to fail or the combined company to under-perform. Prominent risks include antitrust hurdles, integration complexity, cost overruns, talent retention, tax treatment, and potential litigation.
Accounting treatment: Because the information is furnished under Item 7.01 (Regulation FD) rather than 1.01 (Entry into a Material Definitive Agreement), it is not deemed “filed” for Section 18 liability.
Take-away: The announcement signals Waters’ intent to accelerate growth through a transformative acquisition, but material uncertainties remain until financial terms, financing structure, and regulatory feedback are disclosed.
Waters Corp. (NYSE: WAT) has filed a Form 4 indicating that director Wei Jiang acquired 68.35 common-stock units on 30 June 2025. The units were issued at a stated price of $0.00 because they represent deferred, stock-settled compensation in lieu of cash director fees under the company’s 1996 Non-Employee Director Deferred Compensation Plan. Each unit converts into one share of common stock on 1 January 2035, in line with the reporting person’s prior deferral election. Following the issuance, Jiang’s direct beneficial ownership rises to 2,478.57 shares. No derivative securities were bought or sold, and no shares were disposed of. The filing reflects a routine, low-dollar insider acquisition that marginally increases director equity alignment but is not material to Waters’ overall share count or valuation.
Waters Corp (WAT) filed a Form 4 on 26 June 2025 for insider Robert L. Carpio III, Senior Vice President of the Waters Division. On 24 June 2025, the company withheld 134 shares of common stock (transaction code F) at $346.80 per share to cover tax obligations associated with the vesting of previously granted restricted stock units. The withholding represents an estimated tax value of roughly $46.5 thousand. Following the transaction, Carpio directly owns 2,656 shares of WAT. No open-market trading or derivative activity was reported, indicating the event is administrative rather than strategic.